aj-vinorelbine solution
agila jamp canada inc - vinorelbine (vinorelbine tartrate) - solution - 10mg - vinorelbine (vinorelbine tartrate) 10mg - antineoplastic agents
vinorelbine 10mg/ml concentrate for solution for infusion concentrate for solution for infusion
accord healthcare limited - vinorelbine (vinorelbine tartrate) - concentrate for solution for infusion - 10mg/ml
vinorelbine 10mg/ml concentrate for solution for infusion concentrate for solution for infusion
accord healthcare limited - vinorelbine (vinorelbine tartrate) - concentrate for solution for infusion - 10mg/ml
vinorelbine accord 20 mg soft capsules
accord healthcare ireland ltd. - vinorelbine tartrate - capsule, soft - vinorelbine
vinorelbine accord 30 mg soft capsules
accord healthcare ireland ltd. - vinorelbine tartrate - capsule, soft - vinorelbine
vinorelbine ebewe
sandoz new zealand limited - vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml of vinorelbine - concentrate for injection - 10 mg/ml - active: vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml of vinorelbine excipient: water for injection - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first-line treatment for advanced non-small cell lung cancer, as a single agent or in combination.
vinorelbine injection solution concentrate
teva parenteral medicines, inc. - vinorelbine tartrate (unii: 253gqw851q) (vinorelbine - unii:q6c979r91y) - vinorelbine 10 mg in 1 ml
vinorelbine injection
ingenus pharmaceuticals, llc - vinorelbine tartrate (unii: 253gqw851q) (vinorelbine - unii:q6c979r91y) - vinorelbine injection is indicated: - in combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) - as a single agent for the treatment of patients with metastatic nsclc none risk summary based on findings from animal studies and its mechanism of action [see clinical pharmacology (12.1)], vinorelbine injection can cause fetal harm when administered to a pregnant woman. available human data are insufficient to inform the drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with administration of vinorelbine at doses approximately 0.33 and 0.18 times the human therapeutic dose, respectively (see data). advise pregnant women of the potential risk to a fetus. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are
vinorelbine strides 10mg per ml (1ml vial)
strides arcolab international limited unit 4, metro centre, tolpits lane, watford, hertfordshire, wd 189 ss, united kingdom - vinorelbine tartrate - concentrate for solution for infusion - vinorelbine tartrate 10 mg/ml - antineoplastic agents
vinorelbine strides 10mg per ml (5ml vial)
strides arcolab international limited unit 4, metro centre, tolpits lane, watford, hertfordshire, wd 189 ss, united kingdom - vinorelbine tartrate - concentrate for solution for infusion - vinorelbine tartrate 10 mg/ml - antineoplastic agents